NRG-GY005: Ovarian, fallopian tube, or primary peritoneal cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out how well the combination of the study drugs, cediranib and olaparib, work compared to standard chemotherapy.
What is the Condition Being Studied?
Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who Can Participate in the Study?

Adult women who have recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer.

Age Group
Adults

What is Involved?

If you choose to join this study you will:
- Be randomized (like a flipping a coin) into one of the following groups::
-- Group 1: receive standard chemotherapy
-- Group 2: receive a combination of the study drugs cediranib and olaparib
- Have blood drawn
- Get a CT scan every two months

-Group 2 participants will also:
-- Have a urine test
-- Have an ECG (to measure the activity of the heartbeat)
-- Take their blood pressure twice a day and record it
-- Complete follow-up phone calls once a week for 12 weeks

Study Details

Full Title
NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Principal Investigator
Gynecologic Oncologist
Protocol Number
IRB: PRO00070645
NCT: NCT02502266
Phase
Phase II/III
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698